editorial
Fourteen years of evolution of ESMO Guidelines: from the minimum recommendations to the Consensus Conference-derived guidelines introduction During the last two decades various Clinical Practice Guidelines (CPGs) have been developed by professional associations, institutions or medical societies at an international, national or regional level.
CPGs are defined as 'systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances' [1] . CPGs are based on the evidence-based medicine system and are a tool for transferring evidence from clinical research into practice and for influencing practitioner's attitude [2] .
As a matter of fact, CPGs are intended: (i) to assist practitioners in appropriate clinical decision making; (ii) to improve quality of healthcare and outcomes for patients; and (iii) to influence national policies for efficient allocation of resources and for better delivery systems [3] . As Eisenberg and Power pointed out, CPGs are intended to provide the right care, at the right time, for the right person and in the right way [4] .
The development process of CPGs in not homogeneous among the internationally available guidelines. The differences are mainly related to several methodological issues, such as multidisciplinarity, production process, etc. Not all CPGs are produced through a systematic review of evidence, a process that consists of (i) formulation of a clinical question/ problem; (ii) identification of relevant papers by support staff and an expert taskforce; (iii) tabulation and synthesis of evidence by methodological experts; and (iv) process of CPGs, drafting by the experts. On the other hand, some CPGs are also developed through a narrative literature search.
Heterogeneity in the development of CPGs is a vital issue. In a recent report, nine well-known CPGs (ASCO, ESMO, NICE, SIGH, START, NHMRC, NCI, NCCN and CCO) and three representative tumors (advanced breast, lung and colon cancer) were selected and scrutinized. Results have shown that a diverse heterogeneity in development, structure, target user and endpoints was prominent among them [5] .
CPGs should be properly and effectively implemented and disseminated in order to be adequately incorporated into daily clinical practice. This can be achieved by: (i) direct mailing; (ii) publication in journals or newsletters; (iii) organization or sponsoring of scientific events; (iv) training by opinion leaders; (v) publicizing to patients or the public; and (vi) integration in recertification or licensing examinations.
Assessment of the quality of the process of development and reporting of CPGs is of paramount importance taking into account their benefits, harm, costs and practicalities. An example is the AGREE Instrument (Appraisal of Guidelines Research and Evaluation) that was established in 1998. In addition, due to both cultural and organizational differences that could exist among countries, a 'trans-contextual adaptation' strategy has been suggested by the ADAPTE framework [6] .
historical development of ESMO CPGs

1998
The original idea for the creation of the ESMO Clinical Guidelines came from Professor Heine H. Hansen via the Central European Task Force in 1998. In particular, he visualized the need for clinical recommendations that might be more practical in daily use. This was supported at a meeting of the ESMO national representatives, who felt that the development of guidelines would contribute to the standing of medical oncology in Europe. the structure and function of the ESMO GLWG through the years
The structure of the GLWG consists of: (i) the Editorial Board; (ii) the Subject Editors; (iii) the authors; and (iv) the reviewers (five reviewers for each CPG). Both authors and reviewers are on a multidisciplinary platform and should all be ESMO Faculty members (Figure 1 ). The process of ESMO CPG development is demonstrated in Table 1 . Nearly 14 years after the inception of the ESMO Guidelines Task Force, 54 clinical guidelines (GLs) were freely available on the ESMO website and in Annals of Oncology.
The initial vision of ESMO GLs was not to compete with other national or international GLs, but to be complementary recommendations to other existing guidelines and to continue to be used in day-to-day practice; in other words, ESMO GLs were based on a philosophy of providing basic and practical information to oncologists and protecting them from 'what and how not to do things'. Therefore, ESMO GLs were at that time called 'ESMO Minimum Clinical Recommendations' and included GLs: (i) of a short size (1-3 pages); (ii) annually published in Annals of Oncology and on the ESMO website; (iii) produced by and dedicated to medical oncologists; and (iv) covering most tumor types.
Since preselected questions on specific tumor types. The objective of these conferences is to address difficult issues using a much wider input from the oncology community by utilizing 30-40 experts. Up to now eight Consensus Conferences have taken place in various European cities (Table 2) . Recently, it has also been proposed that ESMO GLs will be called 'ESMO Clinical Practice Guidelines (CPGs)' and all GLs will be available on the ESMO website and only the updated ESMO CPGs will be published annually in Annals of Oncology (Table 3) . ESMO Consensus Conference-derived CPGs will also appear in Annals of Oncology [7] [8] [9] [10] .
Based on the lessons learned from the first Consensus Conferences, a detailed Standard Operating Procedures platform has been developed and will be implemented from 2011 onwards.
implementation of ESMO CPGs
Successful establishment of guidelines requires both adequate implementation and sufficient dissemination. Effective The number of downloads from data extracted form the Oxford Journals usage statistics through the years showed an exponential increase (Figure 2 Universally the three most highly ranked countries are the USA, Italy and Switzerland. Geographical breakdown by continent showed that Europe is by far the most highly ranked continent accounting for almost the half of the downloads (Table 5) . It is also interesting to point out that the total usage in North America is mostly attributed to the USA (84%) and only 16% to Canada. Concerning the European geographical distribution, Italy, Switzerland and Germany are the three nations with the highest percentage usage (Table 6) .
Another tool used to evaluate the spectrum of implementation was a survey/questionnaire given during the ESMO Congresses ( Table 7 ). The first three questions, asked at the onset, were related to audience exposure to ESMO clinical recommendations, while the seven questions asked at the end of the session were taken from the survey of Tunis et al. [11] . This questionnaire was prepared to assess the familiarity, confidence and attitudes relating to ESMO CPGs. More than 80% of the responders feel that ESMO CPGs are helpful for their daily practice, 85% believe that they are also a good educational tool, and 95% think that they are intended to improve patients' quality of care.
dissemination of ESMO CPGs
During the last several years ESMO CPGs have been disseminated using different methodological tools. The first tool is the translation of ESMO CPGs into various languages. Up to now they have been translated into 13 languages (Bulgarian, Chinese, French, German, Greek, Italian, Japanese, Latvian, Polish, Portuguese, Romanian, Russian and Spanish).
The second tool is the organization of the ESMO interactive sessions during the ESMO Congresses. In these 2 h interactive events 2-3 cases on various tumors or other oncology topics are presented by a young medical oncologist and discussed by an expert European oncologist based on the ESMO CPGs. Each case is followed by three multiple-choice questions which should first be answered by the audience through an electronic voting system. All these sessions are well attended and it is worth mentioning that at the 35th ESMO Congress in Milan in 2010, the audience had increased up to 3200 attendees ( Table 8) . The third tool is the presentation of ESMO CPGs by members of the GLWG in Congresses Symposia or other scientific events both in and outside Europe.
The last tool of dissemination of ESMO CPGs is the publication of editorials or articles in oncology journals. The aims are to increase the awareness of the European and international oncological societies about the availability, the quality and the utility of ESMO CPGs.
future developments
ESMO is introducing new ideas on CPG implementation and dissemination by producing pocket-sized booklets and mobile apps. Pocket-sized booklets will present the key information from CPG/Consensus manuscripts in a quick references format including treatment algorithms and all recommendations.
Mobile apps will present the information in pocket versions in SmartPhone and other app formats for use on mobile devices.
In addition, ESMO is aiming to produce CPG slide-sets for use by ESMO members as a teaching resource. Good clinical guidelines can have a deep impact on the quality of cancer care in a community. Moreover, if the recommendations provided are well implemented, this may eventually have a potential benefit in cancer outcomes. For this reason, ESMO is committed to produce high quality, evidence-based guidelines to offer a useful tool to the whole oncology community. Our aim is to help in keeping clinical practice within the current understanding and best science in a multidisciplinary setting. To provide such an instrument, a tremendous effort has to be made and a long, controlled process has to be organized every year with the cooperation of authors, reviewers, Subject Editors and ESMO officers. The final product of this cooperative undertaking has to benefit not only oncologists, helping them in optimal clinical practice, but also patients, giving them the opportunity for the best possible outcomes. 
